BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m(2) and irinotecan 60 mg/m(2), intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens. 2009 American Cancer Society.
BACKGROUND:Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m(2) and irinotecan 60 mg/m(2), intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). CONCLUSIONS:Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens. 2009 American Cancer Society.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Ricardo Hitt; Maria L Amador; Miguel Quintela-Fandino; Antonio Jimeno; Olga del Val; Susana Hernando; Hernan Cortes-Funes Journal: Cancer Date: 2006-01-01 Impact factor: 6.860
Authors: N Yamamoto; M Fukuoka; S-I Negoro; K Nakagawa; H Saito; K Matsui; M Kawahara; H Senba; Y Takada; S Kudoh; T Nakano; N Katakami; T Sugiura; T Hoso; Y Ariyoshi Journal: Br J Cancer Date: 2004-01-12 Impact factor: 7.640
Authors: A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim Journal: Ann Oncol Date: 2012-08-16 Impact factor: 32.976
Authors: Jill Gilbert; Ju Whei Lee; Athanassios Argiris; Missak Haigentz; Lawrence Eric Feldman; Minyoung Jang; Pattatheyil Arun; Carter Van Waes; Arlene A Forastiere Journal: Head Neck Date: 2012-07-13 Impact factor: 3.147
Authors: A Argiris; S Li; M Ghebremichael; A M Egloff; L Wang; A A Forastiere; B Burtness; R Mehra Journal: Ann Oncol Date: 2014-05-05 Impact factor: 32.976
Authors: Benoist Chibaudel; Roger Lacave; Marine Lefevre; Patrick Soussan; Martine Antoine; Sophie Périé; Jean-Baptiste Belloc; Alain Banal; Sébastien Albert; Frédéric Chabolle; Philippe Céruse; Philippe Baril; Michel Gatineau; Martin Housset; Rachel Moukoko; Magdalena Benetkiewicz; Aimery de Gramont; Franck Bonnetain; Jean Lacau St Guily Journal: Cancer Med Date: 2015-02-14 Impact factor: 4.452